Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AstraZeneca
AZN
|
+$693M |
| 2 |
Constellation Brands
STZ
|
+$368M |
| 3 |
Tesla
TSLA
|
+$332M |
| 4 |
NVIDIA
NVDA
|
+$300M |
| 5 |
Booking.com
BKNG
|
+$251M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Charter Communications
CHTR
|
+$821M |
| 2 |
Netflix
NFLX
|
+$777M |
| 3 |
AbbVie
ABBV
|
+$583M |
| 4 |
Bristol-Myers Squibb
BMY
|
+$477M |
| 5 |
FedEx
FDX
|
+$456M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 21.07% |
| 2 | Consumer Discretionary | 17.72% |
| 3 | Financials | 13.25% |
| 4 | Healthcare | 11.94% |
| 5 | Communication Services | 11.79% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
PXD
401
DELISTED
Pioneer Natural Resource Co.
PXD
| $20.3M | 0.02% |
107,052
-3,890
| -4% | -$745K |
|
402
Oracle
ORCL
$346B
| $20.2M | 0.02% |
458,347
-339,521
| -43% | -$15.6M |
|
403
BioCryst Pharmaceuticals
BCRX
$2.48B
| $19.9M | 0.02% |
3,471,438
-33,157
| -0.9% | -$183K |
|
404
B&G Foods
BGS
$297M
| $19.9M | 0.02% |
665,042
+249,502
| +60% | +$6.7M |
|
405
Core Laboratories
CLB
$493M
| $19.8M | 0.02% |
156,534
-5,915
| -4% | -$720K |
|
406
Benchmark Electronics
BHE
$2.76B
| $19.7M | 0.02% |
677,498
-77,094
| -10% | -$2.21M |
|
407
BrightView Holdings
BV
$1.3B
| $19.6M | 0.02% |
+890,688
| New | +$19.3M |
|
|
MRNS
408
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $19.5M | 0.02% |
689,339
+5,433
| +0.8% | +$120K |
|
409
Freeport-McMoran
FCX
$88.6B
| $19.3M | 0.02% |
1,118,042
+296,228
| +36% | +$5.02M |
|
410
Kinder Morgan
KMI
$70.3B
| $19.2M | 0.02% |
1,088,031
+204,895
| +23% | +$3.35M |
|
411
Axogen
AXGN
$2.19B
| $18.9M | 0.02% |
375,636
+364,928
| +3,408% | +$16.1M |
|
|
VR
412
DELISTED
Validus Hold Ltd
VR
| $18.7M | 0.02% |
276,954
-242,707
| -47% | -$16.4M |
|
413
Independence Realty Trust
IRT
$3.93B
| $18.3M | 0.02% |
1,779,026
+50,155
| +3% | +$483K |
|
414
First Bancorp
FBNC
$2.66B
| $17.8M | 0.02% |
434,535
+24,066
| +6% | +$953K |
|
|
CONE
415
DELISTED
CyrusOne Inc Common Stock
CONE
| $17.7M | 0.02% |
304,025
-717,856
| -70% | -$38.9M |
|
416
Cardlytics
CDLX
$22.3M
| $17.5M | 0.02% |
80,628
-501
| -0.6% | -$92.7K |
|
|
FMI
417
DELISTED
Foundation Medicine, Inc.
FMI
| $17.3M | 0.02% |
126,761
+1,665
| +1% | +$151K |
|
418
Western Midstream Partners
WES
$19.4B
| $17.3M | 0.02% |
+483,943
| New | +$17M |
|
|
TSRO
419
DELISTED
TESARO, Inc.
TSRO
| $17.2M | 0.02% |
385,748
-3,837
| -1% | -$186K |
|
|
GSKY
420
DELISTED
GreenSky, Inc. Class A Common Stock
GSKY
| $16.9M | 0.02% |
+800,000
| New | +$19.2M |
|
421
Wingstop
WING
$3.67B
| $16.7M | 0.02% |
320,709
-159,655
| -33% | -$8.13M |
|
|
TCDA
422
DELISTED
Tricida, Inc. Common Stock
TCDA
| $16.7M | 0.02% |
+557,319
| New | +$15.6M |
|
423
Tenaris
TS
$28.1B
| $16.6M | 0.02% |
457,060
-186,536
| -29% | -$6.91M |
|
424
Fortinet
FTNT
$110B
| $16.5M | 0.02% |
1,325,305
-2,883,965
| -69% | -$34.2M |
|
425
Monolithic Power Systems
MPWR
$63B
| $16.4M | 0.02% |
122,827
-6,877
| -5% | -$876K |
|
Similar funds
Jennison Associates's Q2 2018 Portfolio in Review
As of Q2 2018, Jennison Associates held 740 positions worth $103B, up 2% from $101B the previous quarter. Its ten largest holdings account for 29% of the portfolio.
Jennison Associates withdrew a net $3.95B in Q2 2018, closing 87 positions and reducing 296 holdings. Its most notable exit was Great Plains Energy Incorporated, an estimated $152M position sold in full.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 21% a quarter earlier, followed by Consumer Discretionary and Financials.
Against the trend, Jennison Associates opened a new position in AstraZeneca worth $677M.
- Jennison Associates's largest Q2 2018 buy was AstraZeneca: 9,637,084 shares worth $677M.
- Jennison Associates added most to Constellation Brands in Q2 2018, an estimated $368M increase.
- Jennison Associates's biggest Q2 2018 reduction was Charter Communications, cutting an estimated $821M.
- Jennison Associates fully exited Great Plains Energy Incorporated in Q2 2018, selling an estimated $152M.
- Jennison Associates's ten largest holdings make up 29% of its $103B portfolio in Q2 2018.
- Jennison Associates opened 89 new positions and closed 87 in Q2 2018.
- Jennison Associates's portfolio value rose 2% quarter-over-quarter to $103B.
Based on Jennison Associates's 13F filing for Q2 2018, filed 2 Aug 2018.